These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20878079)

  • 1. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level.
    Wang Z; Liu M; Zhu H; Zhang W; He S; Hu C; Quan L; Bai J; Xu N
    Int J Oncol; 2010 Nov; 37(5):1315-21. PubMed ID: 20878079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein.
    Xiong J; Du Q; Liang Z
    Oncogene; 2010 Sep; 29(35):4980-8. PubMed ID: 20562918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
    Gibcus JH; Kroesen BJ; Koster R; Halsema N; de Jong D; de Jong S; Poppema S; Kluiver J; Diepstra A; van den Berg A
    J Pathol; 2011 Dec; 225(4):609-17. PubMed ID: 21953646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myc suppressed E-cadherin through miR-9 at the post-transcriptional level.
    Liu M; Zhu H; Yang S; Wang Z; Bai J; Xu N
    Cell Biol Int; 2013 Mar; 37(3):197-202. PubMed ID: 23364919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
    Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Myc-regulated microRNAs modulate E2F1 expression.
    O'Donnell KA; Wentzel EA; Zeller KI; Dang CV; Mendell JT
    Nature; 2005 Jun; 435(7043):839-43. PubMed ID: 15944709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
    Gery S; Tanosaki S; Bose S; Bose N; Vadgama J; Koeffler HP
    Clin Cancer Res; 2005 May; 11(9):3184-90. PubMed ID: 15867211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
    Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
    Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
    Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNA-451 plays a role as tumor suppressor in human glioma cells.
    Nan Y; Han L; Zhang A; Wang G; Jia Z; Yang Y; Yue X; Pu P; Zhong Y; Kang C
    Brain Res; 2010 Nov; 1359():14-21. PubMed ID: 20816946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of miR-20a on p21: Two Mechanisms Blocking Growth Arrest in TGF-β-Responsive Colon Carcinoma.
    Sokolova V; Fiorino A; Zoni E; Crippa E; Reid JF; Gariboldi M; Pierotti MA
    J Cell Physiol; 2015 Dec; 230(12):3105-14. PubMed ID: 26012475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
    Mitchell KO; El-Deiry WS
    Cell Growth Differ; 1999 Apr; 10(4):223-30. PubMed ID: 10319992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers.
    Sakurai K; Furukawa C; Haraguchi T; Inada K; Shiogama K; Tagawa T; Fujita S; Ueno Y; Ogata A; Ito M; Tsutsumi Y; Iba H
    Cancer Res; 2011 Mar; 71(5):1680-9. PubMed ID: 21189327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
    Li H; Wu X
    Biochem Biophys Res Commun; 2004 Nov; 324(2):860-7. PubMed ID: 15474507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AP4 encodes a c-MYC-inducible repressor of p21.
    Jung P; Menssen A; Mayr D; Hermeking H
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15046-51. PubMed ID: 18818310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation.
    Feng M; Li Z; Aau M; Wong CH; Yang X; Yu Q
    Oncogene; 2011 May; 30(19):2242-51. PubMed ID: 21242960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
    Chen L; Li C; Zhang R; Gao X; Qu X; Zhao M; Qiao C; Xu J; Li J
    Cancer Lett; 2011 Oct; 309(1):62-70. PubMed ID: 21664042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
    Wang Z; Ge L; Wang M; Carr BI
    J Cell Physiol; 2006 Jul; 208(1):133-40. PubMed ID: 16596619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R; Chen JM; Huard S; Wang E
    J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.